Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 156 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PAZOPANIB Clear all
Completed Phase 1Phase 2 Interventional Results available

A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma

NCT01975519
View directory record Official record
Conditions
Advanced Soft Tissue Sarcoma
Interventions
TRC105 and Pazopanib
Drug
Lead sponsor
Tracon Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 120 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

NCT01639911
View directory record Official record
Conditions
Malignant Neoplasm of Breast, CNS Malignancy, Malignant Neoplasm of Gastrointestinal Tract, Genitourinary Neoplasms Malignancy and Gender Unspecified, Head and Neck Neoplasms, Melanoma, Malignant Neoplasm of Thorax
Interventions
Alisertib, Pazopanib
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 22, 2019 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional

Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies

NCT01339871
View directory record Official record
Conditions
Advanced Cancer
Interventions
Pazopanib, Vorinostat
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 3 Interventional Results available

Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy

NCT00753688
View directory record Official record
Conditions
Sarcoma, Soft Tissue
Interventions
PAZOPANIB, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional

A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors

NCT00619424
View directory record Official record
Conditions
Lung Cancer, Non-Small Cell
Interventions
pazopanib, erlotinib, pemetrexed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Aurora, Colorado • Buffalo, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 17, 2017 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Not applicable Interventional

Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)

NCT00749320
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Arterial Spin Labeling Magnetic Resonance Imaging
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

NCT00732420
View directory record Official record
Conditions
Solid Tumours
Interventions
topotecan, pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

NCT01931098
View directory record Official record
Conditions
Glioblastoma, Glioblastoma Multiforme, Gliosarcoma, Brain Neoplasms, Central Nervous System Neoplasms
Interventions
topotecan, pazopanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

NCT02180867
View directory record Official record
Conditions
Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma, Clear Cell Sarcoma of Soft Tissue, Epithelioid Malignant Peripheral Nerve Sheath Tumor, Epithelioid Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Extraskeletal Osteosarcoma, Fibrohistiocytic Neoplasm, Fibrosarcoma, Inflammatory Myofibroblastic Tumor, Intimal Sarcoma, Leiomyosarcoma, Liposarcoma, Liver Embryonal Sarcoma, Low Grade Fibromyxoid Sarcoma, Low Grade Myofibroblastic Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Malignant Skin Granular Cell Tumor, Malignant Triton Tumor, Mesenchymal Chondrosarcoma, Myxofibrosarcoma, Myxoid Chondrosarcoma, Myxoinflammatory Fibroblastic Sarcoma, Nerve Sheath Neoplasm, PEComa, Pericytic Neoplasm, Plexiform Fibrohistiocytic Tumor, Sclerosing Epithelioid Fibrosarcoma, Skin Glomus Tumor, Stage IB Soft Tissue Sarcoma AJCC v7, Stage IIB Soft Tissue Sarcoma AJCC v7, Stage III Soft Tissue Sarcoma AJCC v7, Stage IV Soft Tissue Sarcoma AJCC v7, Synovial Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Ifosfamide, Pazopanib, Pazopanib Hydrochloride, Radiation Therapy, Therapeutic Conventional Surgery
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
365
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 240 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 23, 2026, 11:34 AM EDT
Terminated Phase 1 Interventional

Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors

NCT01407562
View directory record Official record
Conditions
Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female
Interventions
Pazopanib, Paclitaxel, Carboplatin
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Pazopanib in Renal Cell Carcinoma

NCT01361113
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Results available

Phase I Trial of Oral Metronomic Topotecan and Oral Pazopanib to Treat Recurrent/Persistent Gynecologic Tumors

NCT00800345
View directory record Official record
Conditions
Gynecologic Tumors
Interventions
Oral Topotecan, Pazopanib
Drug
Lead sponsor
Vector Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

NCT01330966
View directory record Official record
Conditions
Chondrosarcoma, Metastatic Chondrosarcoma
Interventions
pazopanib
Drug
Lead sponsor
Emerald Clinical Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
6
States / cities
Duarte, California • Naperville, Illinois • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional

GW786034 in Treating Patients With Advanced Solid Tumors

NCT00060151
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
pazopanib hydrochloride
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
21 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
2
States / cities
Durham, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib in Previously Treated Patients With Metastatic Renal Cell Carcinoma

NCT00731211
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pazopanib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
17
States / cities
San Francisco, California • Fort Myers, Florida • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

NCT02009449
View directory record Official record
Conditions
Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma, Colorectal Carcinoma, Pancreatic Carcinoma, Non-small Cell Lung Carcinoma, Solid Tumors, Breast Cancer
Interventions
Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil), gemcitabine/nab-paclitaxel, Capecitabine, Pazopanib, Pembrolizumab, Paclitaxel, nivolumab, Gemcitabine/carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 11:34 AM EDT
Terminated Not applicable Interventional Results available

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

NCT01599832
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
pazopanib hydrochloride, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, pharmacogenomic studies
Drug · Other · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Chicago, Illinois • Decatur, Illinois • Harvey, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

NCT01236547
View directory record Official record
Conditions
Thyroid Gland Anaplastic Carcinoma
Interventions
Intensity-Modulated Radiation Therapy, Paclitaxel, Pazopanib Hydrochloride, Placebo Administration
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
130
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety Study to Evaluate Pazopanib Eye Drops in Healthy Volunteers

NCT01072214
View directory record Official record
Conditions
Macular Degeneration
Interventions
pazopanib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
20 Years to 64 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

NCT01027598
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Pazopanib, Erlotinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
8
States / cities
Fort Myers, Florida • Lawrenceville, Georgia • Cincinnati, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 2 Interventional Results available

Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

NCT01262820
View directory record Official record
Conditions
Lung Cancer
Interventions
Pazopanib
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 7, 2017 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 23, 2026, 11:34 AM EDT
Terminated Phase 1 Interventional

A Combination of Pazopanib and Carboplatin in Advanced Solid Malignancies

NCT01542047
View directory record Official record
Conditions
Cancer, Metastatic
Interventions
Carboplatin, Pazopanib
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 23, 2026, 11:34 AM EDT
Completed Phase 4 Interventional Results available

VEG113971: An Open-Label Study of the Effects of Ketoconazole or Esomeprazole on Pazopanib PK

NCT01205230
View directory record Official record
Conditions
Cancer
Interventions
pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
New Brunswick, New Jersey • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated May 22, 2012 · Synced Oct 23, 2026, 11:34 AM EDT